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Background-—Although it has been reported that renal function can improve after catheter ablation of atrial ﬁbrillation (AF), long-
term changes in renal function and its relationship to rhythm outcomes have not yet been evaluated. We explored the 5-year
change in estimated glomerular ﬁltration rate (eGFR) in AF patients depending on medical therapy and catheter ablation.
Methods and Results-—Among 1963 patients who underwent AF catheter ablation and 14 056 with AF under medical therapy in
the National Health Insurance Service database, we compared 571 with AF catheter ablation (5910 years old, 72.3% male, and
66.5% paroxysmal AF) and 1713 with medical therapy after 1:3 propensity-score matching. All participants had 5 years of serial
eGFR data (Chronic Kidney Disease-Epidemiology Collaboration [CKD-EPI] method). Catheter ablation improved eGFR5 yrs
(P<0.001), but medical therapy did not. In 2284 matched patients, age (adjusted odds ratio [OR], 0.98 [0.97–0.99]; P<0.001) and
AF catheter ablation (adjusted OR, 2.02 [1.67–2.46]; P<0.001) were independently associated with an improved eGFR5 yrs. Among
571 patients who underwent AF ablation, freedom from AF/atrial tachycardia recurrence after the last AF ablation procedure was
independently associated with an improved eGFR5 yrs (adjusted OR, 1.44 [1.01–2.04]; P=0.043), especially in patients without
diabetes mellitus (adjusted OR, 1.78 [1.21–2.63]; P=0.003, P for interaction=0.012). Although underlying renal dysfunction
(<60 mL/min/1.73m2) was associated with atrial structural remodeling (adjusted OR, 1.05 [1.00–1.11]; P=0.046), it did not affect
the AF ablation rhythm outcome.
Conclusions-—AF catheter ablation signiﬁcantly improved renal function over a 5-year follow-up, especially in patients maintaining
sinus rhythm without preexisting diabetes mellitus. ( J Am Heart Assoc. 2019;8:e013204. DOI: 10.1161/JAHA.119.013204.)
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A trial ﬁbrillation (AF), a common arrhythmia thatincreases mortality by 2 to 3 times,1 is a progressive
degenerative disease2 associated with strokes,1 dementia,1
and heart failure.1 Chronic kidney disease (CKD) has a well-
established association with cardiovascular disease, and all-
cause mortality and cardiovascular mortality progressively
increase as renal function declines.3,4 It has been shown that
7% to 18% of patients with a CKD stage of ≥3 (estimated
glomerular ﬁltration rate [eGFR] <60 mL/min/1.73 m2) have
concomitant AF, and 10% to 15% of AF patients have CKD.5–7
This relationship becomes more signiﬁcant for those aged
>70 years. Patients with both AF and CKD have an increased
risk of bleeding and thromboembolisms.7 Washam et al8
reported that AF rhythm control by antiarrhythmic drugs did
not affect all-cause mortality and risk of a stroke in patients in
the ORBIT-AF (Outcomes Registry for Better Informed Treat-
ment of Atrial Fibrillation) registry data. In contrast, AF
catheter ablation has been known to be a more-effective
method of AF rhythm control than antiarrhythmic drugs,9 and
it is known to lower the heart failure mortality10,11 and risk of
cerebral infarctions12 and improve the cognitive function.13,14
However, studies on renal-function changes after AF rhythm
control by catheter ablation have been limited thus far.
Takahashi et al reported that maintenance of sinus rhythm
after a single AF catheter ablation resulted in a positive effect
on renal function.15 After a successful AF ablation, left
ventricular systolic function improves and mean heart rate
increases because of autonomic nerve modulation.16,17 As a
result, cardiac output increases, and a positive effect on renal
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ORIGINAL RESEARCH
function is expected after a successful AF ablation. However,
given that AF has a substantial long-term recurrence rate after
catheter ablation, there are no data on changes in renal
function over a 5-year long-term period or after repeated
procedures. Therefore, we hypothesized that an optimal AF
rhythm control, including a repeat ablation, may improve long-
term renal function beyond 5 years. In this study, we
compared the change in renal function in AF patients who
underwent catheter ablation followed by a guideline-based
regular rhythm follow-up (Yonsei AF ablation cohort) and
those that underwent medical therapy alone (Korean National
Health Insurance [NHIS] database) over a peirod of 5 years.
We also explored the relationship of the change in long-term
renal function after AF catheter ablation to rhythm outcome or
degree of atrial remodeling.
Methods
The data, analytic methods, and study materials that support
the ﬁndings of this study are available from the corresponding
author upon reasonable request.
Study Population
This study protocol adhered to the principles of the Decla-
ration of Helsinki and was approved by the Institutional
Review Board of the Yonsei University Health System. The
medical therapy group was selected from the NHIS database
(NHIS-2018-2-189), and the ablation therapy group was
selected from the Yonsei AF Ablation cohort (registered at
ClinicalTrials.gov Identiﬁer: NCT02138695). Both groups were
enrolled as nonvalvular AF patients with baseline and 5-year
follow-up eGFR (estimated by Chronic Kidney Disease
Epidemiology Collaboration [CKD-EPI] equation) data. In the
AF ablation group, all patients provided written informed
consent for inclusion in the Yonsei AF Ablation study. The
informed consent requirement in the medical therapy group
from the NHIS database was waived. Among 1963 patients
who underwent AF catheter ablation (AFCA) for symptomatic
drug-refractory AF, 571 patients (5910 years, 72.3% male,
and 66.5% paroxysmal AF) who had 5-year serial eGFR data
after AF ablation were enrolled in this study. All patients
stopped their antiarrhythmic drugs for a period of time
corresponding to at least 5 half-lives before catheter ablation.
During the 5-year follow-up period, 103 patients underwent a
second ablation, and 3 underwent a third ablation for
antiarrhythmic-resistant recurrent AF (Figure 1). In the med-
ical therapy group, among 14 056 patients with nonvalvular
AF who were not treated with catheter ablation in the NHIS
database, 1713 patients (5911 years, 73.2% male) who had
both baseline and 5-year follow-up renal function data were
enrolled in this study for the control group after propensity-
score matching with the AF ablation group. Exclusion criteria
were as follows: (1) permanent AF refractory to electrical
cardioversion, (2) AF with rheumatic valvular disease, and (3)
previous cardiac surgery with concomitant AF surgery or AF
catheter ablation.
Electrophysiological Mapping and
Radiofrequency Catheter Ablation
3D electroanatomical mapping (NavX; St. Jude Medical, Inc,
Minnetonka, MN) was generated using a circumferential
pulmonary vein (PV)-mapping catheter (Lasso; Biosense-
Webster Inc, Diamond Bar, CA) through a long sheath (Schwartz
left 1; St. Jude Medical, Inc). Multiview pulmonary venograms
were obtained after the trans-septal punctures. The 3D
geometry of both the left atrium (LA) and PVs was generated
using the NavX system and then merged with 3D spiral
computed tomography images. Systemic anticoagulation with
intravenous heparin was achieved to maintain an activated
clotting time of 350 to 400 seconds during the procedure.
An open-irrigated tip catheter (Celsius; Johnson & Johnson
Inc, Diamond Bar, CA; NaviStar ThermoCool, Biosense Web-
ster Inc; ThermoCool SF, Biosense Webster Inc; ThermoCool
SmartTouch, Biosense Webster Inc; Coolﬂex, St. Jude Medical
Inc; 30–35 W; 47°C; FlexAbility, St Jude Medical Inc;
ThermoCool SmartTouch, Biosense Webster Inc, and Tacti-
Cath, St. Jude Medical Inc) was used for AFCA. All patients
underwent a de novo procedure with a circumferential
pulmonary vein isolation. The majority of the patients
(94.2%) underwent a cavotricuspid isthmus block during the
de novo procedure if there was no atrioventricular conduction
disease. We conducted an additional linear ablation including
a roof line, posterior inferior line (posterior box lesion), and
Clinical Perspective
What Is New?
• Atrial ﬁbrillation (AF) catheter ablation improved renal
function over the 5-year follow-up, whereas medical therapy
did not.
• No recurrence after the last AF ablation procedure was
independently associated with an improved long-term renal
function, especially in patients without diabetes mellitus.
• Impaired renal function was associated with an atrial
structural remodeling in AF patients, but did not affect the
rhythm outcome of AF catheter ablation.
What Are the Clinical Implications?
• AF catheter ablation and reduction of AF burden can
improve renal function over a long-term period, especially in
patients without diabetes mellitus.
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anterior line, especially in patients with persistent AF. A left
lateral isthmus ablation, right atrial ablation, and complex
fractionated electrogram ablation were performed in a
minority of the patients at the operator’s discretion. The de
novo procedure ended when there was no immediate
recurrence of AF within 10 minutes after the cardioversion
with an isoproterenol infusion (5–10 lg/min). In the case of
mappable AF triggers or premature atrial beats, non-PV foci
were carefully mapped and ablated as much as possible.
The detailed technique and strategy for the repeat ablation
procedures were presented in a previous study.18 If there
were reconnections of PV potentials or a previous linear
ablation, we completed the circumferential pulmonary vein
isolation and accomplished bidirectional block of the circum-
ferential pulmonary vein isolation, cavotricuspid isthmus, or
linear ablation as much as possible. Then, we provoked extra-
PV foci with an isoproterenol infusion (5–10 lg/min) and
carefully mapped and ablated mappable AF triggers or
frequent atrial premature beats. If there were multiple extra-
PV triggers, we conducted an additional linear ablation or an
electrogram-guided ablation at the operators’ discretion.
Postablation Management and Follow-up
Patients visited the outpatient clinic at 1, 3, 6, and 12 months
and every 6 months thereafter or whenever symptoms
developed after the AFCA. ECG was performed at every visit.
Twenty-four-hour Holter monitoring was performed at 3, 6,
and 12 months and then every 6 months after the AFCA
according to the 2012 Heart Rhythm Society/European Heart
Rhythm Association/European Cardiac Arrhythmia Society
expert consensus statement guidelines.19 Patients underwent
an annual laboratory examination (serum creatinine, blood
urea nitrogen, urine hemoglobin, and dipstick urine protein).
eGFR was estimated by the CKD-EPI equation. Patients who
suffered from symptoms of palpitations underwent Holter/
event-monitor examinations to investigate the possibility of an
arrhythmia recurrence. We deﬁned an AF recurrence as any
episode of atrial tachycardia (AT) or AF lasting for 30 seconds
or more. Any ECG documentation of an AF recurrence after a
3-month blanking period was classiﬁed as a clinical recur-
rence.
Statistical Analysis
Continuous variables are expressed as meanSD and were
analyzed using a Student t test. Categorical variables are
reported as numbers (percentages) and were analyzed using a
chi-square or Fisher’s exact test. We used a paired t test to
investigate changes in eGFR5 yr (DeGFR5 yr) in both the AFCA
group and control group. Also, we compared DeGFR5 yr after
AFCA according to freedom from AF/AT recurrence by using a
paired t test. A multivariate logistic regression analysis was
used to investigate whether AF catheter ablation improved
renal function and identify predictors associated with an
improvement in renal function in patients who underwent AF
Figure 1. Study ﬂow chart of the patient enrollment. ACEi indicates angiotensin-converting-enzyme inhibitor; AF, atrial ﬁbrillation; AFCA, AF
catheter ablation; ARB, angiotensin type II receptor blocker; eGFR, estimated glomerular ﬁltration rate.
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catheter ablation. The variables with a P value under 0.05
were included in the multivariate model. Furthermore, we did
not use a step-wise selection model in multivariate regression
analysis. A Kaplan–Meier analysis was used to analyze
probability of freedom from AF/AT recurrence after AFCA
according to a concomitant impaired renal function. Propen-
sity matching was performed without a replacement and with
a caliper of 0.01 at a 1: 3 ratio of the AF ablation group and
medical therapy group based on the following variables: age,
sex, body mass index, congestive heart failure, hypertension,
diabetes mellitus, previous history of a stroke or transient
ischemic attack, previous history of vascular disease,
CHA2DS2VASc score, baseline eGFR, and medications, includ-
ing angiotensin-converting enzyme inhibitors, angiotensin
type II receptor blockers, b-blockers, and statins. P<0.05
was considered statistically signiﬁcant. All statistical analyses
were performed using SPSS (version 23.0; SPSS, Inc, Chicago,
IL) software for Windows.
Results
AF Catheter Ablation Versus Medical Therapy
Baseline characteristics in the AF catheter ablation group
and propensity-score–matched control group are presented
in Table 1. There were no signiﬁcant differences in patient
characteristics, medication use, and baseline eGFR between
the AFCA group and medical therapy group. Nonetheless,
eGFR measured at the 5-year follow-up in patients who
underwent AFCA was signiﬁcantly higher than that in patients
with medical therapy (84.619.4 versus 82.418.1 mL/min/
1.73 m2; P=0.014; Figure 2A). DeGFR5 yr was also signiﬁ-
cantly higher in patients with AFCA as compared with patients
with medical therapy (3.213.6 versus 0.716.8 mL/min/
1.73 m2; P<0.001; Figure 2B). Among the overall 2284
patients, a young age (adjusted odds ratio [OR], 0.98 [0.97–
0.99]; P<0.001; Table 2) and AF catheter ablation (adjusted
OR, 2.02 [1.67–2.46]; P<0.001; Table 2) were independently
associated with an improved renal function (DeGFR5 yr,
>0 mL/min/1.73 m2) after the 5-year follow-up after when
adjusting for preexisting hypertension and angiotensin-con-
verting enzyme inhibitor/angiotensin type II receptor blocker
use. We tested the different thresholds of DeGFR5 yr based on
previous studies,15,20–22 and found that AFCA was a consistent
variable of long-term improvement in renal function (Tables S1
through S3).
Patient Characteristics With a Renal Function
Improvement After AFCA
Table 3 summarizes the comparison of baseline characteris-
tics, including echocardiographic parameters and clinical
rhythm outcome of 571 patients according to improvement
in renal function (DeGFR5 yr, >0 mL/min/1.73 m
2). Patients
Table 1. Comparison of the Baseline Characteristics and eGFR in AF Patients With AFCA or Medical Therapy
Overall AFCA Medical therapy
P Value ASMD(n=2284) (n=571) (n=1713)
Age, y 5910 5910 5911.0 0.895 0.006
Male 1667 (73%) 413 (72.3%) 1254 (73.2%) 0.683 0.020
Body mass index 24.83.0 24.92.8 24.83.0 0.312 0.046
CHA2DS2VASc score 1.71.5 1.81.5 1.71.6 0.546 0.029
CHF 110 (4.8%) 30 (5.3%) 80 (4.7%) 0.573 0.027
Hypertension 1163 (50.9%) 290 (50.8%) 873 (51%) 0.942 0.004
Diabetes mellitus 394 (17.3%) 99 (17.3%) 295 (17.2%) 0.949 0.003
Stroke/TIA 263 (11.5%) 67 (11.7%) 196 (11.4%) 0.850 0.009
Vascular disease 336 (14.7%) 92 (16.1%) 244 (14.2%) 0.275 0.052
ACEi/ARB use 862 (37.8%) 206 (36.1%) 656 (38.3%) 0.358 0.046
Beta-blocker use 676 (29.6%) 160 (28.1%) 516 (30.1%) 0.353 0.046
Statin use 653 (28.6%) 160 (28.1%) 493 (28.8%) 0.745 0.017
Baseline eGFR 81.716.9 81.418.5 81.816.3 0.685 0.02
The patients under medical therapy were included in this study after propensity-score matching for the age, sex, body mass index, CHF, hypertension, diabetes mellitus, stroke/TIA,
vascular disease, CHA2DS2VASc score, baseline eGFR, ACEi/ARB use, beta-blocker use, and statin use. ACEi indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; AFCA,
AF catheter ablation; ARB, angiotensin type II receptor blocker; ASMD, absolute standardized mean differences; CHF, congestive heart failure; eGFR, estimated glomerular ﬁltration rate;
TIA, transient ischemic attack.
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whose renal function improved during the 5-year follow-up
were younger (P=0.008), had a lower CHA2DS2VASc score
(P=0.015) and lower hypertension (P=0.003), took less
angiotensin-converting enzyme inhibitors/angiotensin type II
receptor blockers after the de novo ablation procedure
(P=0.046), and were more likely to maintain sinus rhythm
after the last ablation procedure (P=0.036) than those without
renal function improvement.
Factors Associated With Improvement in Renal
Function in Patients That Underwent AFCA
Among the overall 571 patients, 465 underwent a single
ablation procedure and the others underwent multiple proce-
dures during the follow-up period. In the patients with a single
procedure alone, 64.1% (298 of 465) were free from an AF/AT
recurrence, and in the overall patients with single or multiple
Table 2. Logistic Regression Analysis for Variables Predicting an Improved Renal Function (DeGFR5 yr >0) After 5 Years of Follow-
up (n=2284)
Univariate Multivariate Model
OR (95% CI) P Value OR (95% CI) P Value
Age 0.980 (0.972–0.987) <0.001* 0.980 (0.972–0.989) <0.001*
Male 0.915 (0.761–1.101) 0.347
Body mass index 1.015 (0.988–1.044) 0.279
CHA2DS2VASc score 0.946 (0.897–0.999) 0.044*
CHF 0.746 (0.505–1.102) 0.141
Hypertension 0.840 (0.712–0.990) 0.037* 1.005 (0.826–1.222) 0.961
Diabetes mellitus 0.888 (0.714–1.105) 0.288
Stroke/TIA 0.914 (0.706–1.183) 0.494
Vascular disease 1.037 (0.822–1.308) 0.759
ACEi/ARB use 0.801 (0.675–0.949) 0.010* 0.871 (0.715–1.060) 0.169
BB use 0.855 (0.714–1.024) 0.089
Statin use 0.985 (0.821–1.181) 0.870
AFCA 2.021 (1.666–2.450) <0.001* 2.023 (1.666–2.457) <0.001*
The CHA2DS2VASC score was not included in multivariate model in Table 2 because the age and hypertension variables had already been considered to calculate the CHA2DS2VASc score.
ACEi indicates angiotensin-converting enzyme inhibitor; AFCA, atrial ﬁbrillation catheter ablation; ARB, angiotensin type II receptor blocker; BB, beta blocker; CHF, congestive heart failure;
OR, odds radio; TIA, transient ischemic attack.
*Statistical signiﬁcance.
Figure 2. Mean estimated glomerular ﬁltration rate (eGFR) measured at baseline and 5 years of follow-up
between the AFCA and medication groups (A). Comparison of the increase in the eGFR from baseline to
5 years (MeGFR5 yrs) between the AFCA and medication groups (B). AFCA indicates atrial ﬁbrillation
catheter ablation.
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procedures, 64.1% (366/571) were free from an AF/AT
recurrence after the last ablation procedure during the 5-year
follow-up period. Mean follow-up duration after the last
ablation session in the 571 overall patients was
42.421.3 months, and in the 106 patients who underwent
multiple procedures was 27.818.0 months. The 5-year
follow-up eGFR was signiﬁcantly higher than baseline eGFR
in the patients without an AF/AT recurrence in both the
overall ablation group (82.117.8–86.218.8 mL/min/
1.73 m2; P<0.001; Figure 3A) and single-procedure group
(81.417.9–85.219.4 mL/min/1.73 m2; P<0.001; Fig-
ure 3D). However, there was no signiﬁcant improvement in
5-year follow-up eGFR in patients with an AF/AT recurrence
(Figure 3B and 3E). Degree of eGFR increase (DeGFR5 yrs)
was signiﬁcantly greater in patients who remained in sinus
rhythm than in those with an AF/AT recurrence after the last
ablation procedure (4.113.6 versus 1.513.4 mL/min/
1.73 m2; P=0.029; Figure 3C). After adjusting for the
CHA2DS2VASc score and postablation angiotensin-converting
enzyme inhibitor/angiotensin type II receptor blocker use, a
multivariate logistic regression analysis demonstrated that
freedom from an AF/AT recurrence after the last ablation
procedure was independently associated with an improve-
ment in renal function (adjusted OR, 1.44 [1.01–2.04];
P=0.043; Table 4).
Which Patients Exhibit a Signiﬁcant Improvement
in Renal Function After AF Ablation?
We performed subgroup analyses to assess whether main-
taining sinus rhythm after the last ablation procedure in some
groups of patients helped improve 5-year follow-up eGFR. The
analyses showed that the beneﬁcial effect of maintaining
sinus rhythm proved to be more prominent in patients with a
Table 3. Comparison of the Baseline Characteristics, Catheter Ablation, and Clinical Rhythm Outcomes According to an Improved
Renal Function (DeGFR5 yr >0) Among the Overall Patients With AFCA (n=571)
Overall Patients With AFCA Improved Renal Function Nonimproved Renal Function
P Value(n=571) (n=342) (n=229)
Age, y 5910 5810 6010 0.008*
Male 413 (72.3%) 245 (71.6%) 168 (73.4%) 0.652
PAF at procedure 380 (66.5%) 231 (67.5%) 149 (65.1%) 0.538
Body mass index 24.92.8 24.92.9 24.92.8 0.850
Body surface area 1.800.17 1.810.18 1.800.17 0.445
CHA2DS2VASc score 1.81.5 1.71.5 2.01.5 0.015*
Congestive heart failure 30 (5.3%) 13 (3.8%) 17 (7.4%) 0.057
Hypertension 290 (50.8%) 156 (45.6%) 134 (58.5%) 0.003*
Diabetes mellitus 99 (17.3%) 56 (16.4%) 43 (18.8%) 0.457
Stroke/TIA 67 (11.7%) 38 (11.1%) 29 (12.7%) 0.572
Vascular disease 92 (16.1%) 55 (16.1%) 37 (16.2%) 0.981
LA dimension, mm 41.96.1 41.96.1 41.96.1 0.911
LVEF, % 63.48.0 63.37.6 63.58.7 0.785
E/Em 10.65.0 10.65.3 10.64.5 0.999
Postablation ACEi/ARB use 206 (36.1%) 112 (32.8%) 94 (41.0%) 0.046*
Postablation BB use 160 (28.1%) 89 (26.1%) 71 (31%) 0.201
Postablation Statin use 160 (28.1%) 96 (28.2%) 64 (27.9%) 0.957
Postablation AAD use 128 (22.4%) 68 (19.9%) 60 (26.2%) 0.076
Advanced CKD at baseline 67 (11.7%) 33 (9.6%) 34 (14.8%) 0.059
Repeat ablations 106 (18.6%) 70 (20.5%) 36 (15.7%) 0.153
Freedom from AF/AT recurrence after last AFCA 366 (64.1%) 231 (67.5%) 135 (59%) 0.036*
DeGFR5 yr indicates the increase in the eGFR from baseline to 5 years after the AF ablation; AAD, antiarrhythmic drugs; ACEi, angiotensin-converting-enzyme inhibitor; AF, atrial ﬁbrillation;
AFCA, atrial ﬁbrillation catheter ablation; ARB, angiotensin type II receptor blocker; AT, atrial tachycardia; BB, beta blocker; CKD, chronic kidney disease; E/Em, the ratio of the early
diastolic mitral inﬂow velocity (E) to the early diastolic mitral annular velocity (Em); eGFR, estimated glomerular ﬁltration rate; LA, left atrium; LVEF, left ventricular ejection fraction; PAF,
paroxysmal atrial ﬁbrillation; TIA, transient ischemic attack.
*Statistical signiﬁcance.
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CHA2DS2VASc score <2, left atrial diameter <45 mm, or left
ventricular ejection fraction ≥50% and without preexisting
comorbidities, including hypertension, diabetes mellitus, vas-
cular disease, or advanced CKD (eGFR <60 mL/min/
1.73 m2; Figure 4). In particular, the positive effect of rhythm
control on renal function improvement was more pronounced
in patients without diabetes mellitus than in those with
diabetes mellitus (P for interaction=0.012; Figure 4).
Baseline Renal Function and Long-Term Rhythm
Outcome After AF Ablation
We compared advanced CKD (CKD stage ≥3; eGFR <60 mL/
min/1.73 m2) and early CKD (CKD stages 1 and 2; Table 5).
Age, proportion with persistent AF at the de novo procedure,
CHA2DS2VASc score, and proportion with a comorbid disease,
including hypertension, diabetes mellitus, and vascular dis-
ease, and LA dimension, were signiﬁcantly greater in AF
patients with advanced CKD than in those with early CKD
(Table 5). After adjusting for AF type during the de novo
procedure, congestive heart failure, hypertension, diabetes
mellitus, and a previous history of vascular disease, old age
(adjusted OR, 1.11 [1.07–1.15]; P<0.001) and baseline LA
dimension (adjusted OR, 1.05 [1.00–1.11]; P=0.046) were
independently associated with baseline advanced CKD
(Table S4). However, baseline CKD stage did not affect
rhythm outcome of the AF catheter ablation after a single
procedure (log rank, P=0.904) or after multiple procedures
(log rank, P=0.381; Figure S1).
Discussion
Major Findings
In this study, we sought to determine how AF ablation
contributed to long-term renal function as compared with
medical therapy alone by comparing an AF ablation cohort
database and an NHIS database after retrospective propen-
sity-score matching. AF catheter ablation, but not medical
therapy, signiﬁcantly improved 5-year follow-up eGFR, and
this improvement in long-term renal function was more
signiﬁcant in patients who remained in sinus rhythm after the
last AF ablation session and in those without preexisting
diabetes mellitus. We also found that preexisting CKD was
associated with degree of atrial structural remodeling before
the catheter ablation, but did not affect the rhythm outcome
of the AF catheter ablation.
Figure 3. Scatter plot and mean changes in the estimated glomerular ﬁltration rate (eGFR) from baseline to 5 years after AF ablation in the
overall patients without an AF/AT recurrence (A) and those with an AF/AT recurrence (B), and in the single procedure alone group without an
AF/AT recurrence (D) and those with an AF/AT recurrence (E). Comparison of the increase in the eGFR from baseline to 5 years (MeGFR5 yrs)
according to AF/AT recurrence after the AF ablation among the patients with repeat procedures (C) and a single procedure alone (F). ACEi
indicates angiotensin-converting-enzyme inhibitor; AF, atrial ﬁbrillation; AFCA, AF catheter ablation; AT, atrial tachycardia.
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AF and Renal Function
AF and CKD are both progressive degenerative diseases, and
their prevalence increases with age. AF has been reported in
7% to 18% of CKD patients, and 12% to 25% of elderly
individuals over 70 years of age with CKD have AF, which is
2 to 3 times that of the general population.5,23,24 In
contrast, CKD is also associated with 10% to 15% of AF
patients.25 Deterioration of renal function serves as an
independent risk factor that increases AF prevalence, even
in the early stages of CKD.26 It may be because of the
mechanistic association between an impaired renal function
and AF. Both AF and CKD have several common pathophys-
iologies, including neurohormonal activation of the renin-
angiotensin-aldosterone system,27–30 inﬂammatory fac-
tors,31,32 and oxidative stress.33–35 Therefore, AF and renal
dysfunction might adversely affect each other over time. In
addition, CKD is important and clinically challenging in
patients requiring anticoagulation, given that it simultane-
ously raises the thromboembolic and bleeding risks.36
However, given that CKD has a very heterogeneous nature37
and most major clinical trials related to AF management
exclude advanced renal disease directly or indirectly,38 it is
hard to deﬁne a comprehensive treatment policy for AF
patients with CKD.
Renal Function and AF Catheter Ablation
The irregular rhythm of AF reduces myocardial function39 and
microvascular function,40 and a loss of atrial kick causes
negative hemodynamic effects. Therefore, restoring sinus
rhythm may improve renal function by changing the hemody-
namics,41–44 improving ventricular function,16 raising mean
heart rate,17 and reducing inﬂammatory/oxidative
Table 4. Logistic Regression Analysis of the Variables Predicting an Improved Renal Function (DeGFR5 yr >0) After 5 Years of
Follow-up Among the Overall Patients With AFCA (n=571)
Univariate Multivariate Model 1 Multivariate Model 2
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age 0.977 (0.961–0.994) 0.008* 0.984 (0.966–1.001) 0.066
Male 0.917 (0.630–1.335) 0.652
PAF at procedure 1.117 (0.785–1.591) 0.539
Body mass index 1.006 (0.948–1.067) 0.850
Body surface area 1.462 (0.553–3.862) 0.444
CHA2DS2VASc score 0.873 (0.781–0.975) 0.016* 0.898 (0.796–1.015) 0.084
Congestive heart failure 0.493 (0.235–1.035) 0.062
Hypertension 0.595 (0.424–0.834) 0.003* 0.665 (0.421–1.050) 0.080
Diabetes mellitus 0.847 (0.546–1.313) 0.458
Stroke/TIA 0.862 (0.515–1.443) 0.572
Vascular disease 0.994 (0.631–1.567) 0.981
LA dimension 0.998 (0.971–1.026) 0.910
LVEF 0.997 (0.976–1.018) 0.784
E/Em 1.000 (0.966–1.035) 0.999
Postablation ACEi/ARB use 0.702 (0.496–0.994) 0.046* 0.991 (0.626–1.569) 0.970 0.817 (0.558–1.196) 0.298
Postablation BB use 0.786 (0.543–1.138) 0.202
Postablation stain use 1.010 (0.696–1.467) 0.957
Postablation AAD use 0.699 (0.470–1.039) 0.077
Advanced CKD at baseline 0.613 (0.367–1.021) 0.060
Repeat ablations 1.380 (0.887–2.147) 0.154
Freedom from AF/AT recurrence
after last AFCA
1.449 (1.024–2.051) 0.036* 1.408 (0.990–2.002) 0.057 1.436 (1.012–2.037) 0.043*
DeGFR5 yr indicates the increase in the eGFR from baseline to 5 years after AF ablation; AAD, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation;
AFCA, atrial ﬁbrillation catheter ablation; ARB, angiotensin type II receptor blocker; AT, atrial tachycardia; BB, beta blocker; CKD, chronic kidney disease; E/Em, the ratio of the early
diastolic mitral inﬂow velocity (E) to the early diastolic mitral annular velocity (Em); LA, left atrium; LVEF, left ventricular ejection fraction; OR, odds radio; PAF, paroxysmal atrial ﬁbrillation;
TIA, transient ischemic attack.
*Statistical signiﬁcance.
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reactions,20,33,35,45 especially after catheter ablation. Although
there have been multiple clinical studies that evaluated renal
function after AF catheter ablation within 1 to 2 years of follow-
up,15,20–22,46 renal function is hard to determine because eGFR
declines by 0.5 to 1 mL/min/1.73 m2 per year in the general
population and 1 to 2.5 mL/min/1.73 m2 per year in patients
with CKD.47 The present study included a longer-term follow-up
of over 5 years in a higher number of patients, so we were able
to more accurately evaluate the small differences in eGFR
changes than in previous studies. We also conducted a
consistent rhythm-monitoring and follow-up protocol based
on the guidelines over 5 years.19 We found that aggressive
rhythm control and a reduction in AF burden through repeat
ablation sessions were associated with an improved renal
function during the long-term follow-up period. However, such
beneﬁcial effects of strict rhythm control by AF ablation were
not shown in patients with preexisting diabetes mellitus. It
might be because diabetes mellitus is associated with LA
Figure 4. Efﬁcacy of the freedom form AF/AT recurrence after the last AFCA in subgroup
analyses. AF indicates atrial ﬁbrillation; AFCA, AF catheter ablation; ARB, angiotensin type II
receptor blocker; AT, atrial tachyarrhythmia; BMI, body mass index; CHF, congestive heart
failure; CKD, chronic kidney disease; DM, diabetes mellitus; E/Em, the ratio of the early diastolic
mitral inﬂow velocity (E) to the early diastolic mitral annular velocity (Em); LA, left atrium, LVEF,
left ventricular ejection fraction; OR, odds ratio; TIA,transient ischemic attack.
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ﬁbrosis and electroanatomical LA remodeling, which result in
impairment of the LA reservoir and pump function.48,49
Diabetes mellitus is also a well-known risk factor of CKD and
progressive deterioration of renal function.50 These adverse
effects on the heart and kidneys of diabetes mellitus appear to
have little effect on long-term renal function improvement,
despite active AF rhythm control by AFCA.
Limitations
This study had several limitations. It was an observational
cohort study from a single center, so highly selected patients
referred for AF were included in this study. Because we
considered that there was an improvement in renal function in
patients whose DeGFR5 yrs was above 0 mL/min/1.73 m
2,
this study might not be able to represent an improvement in
CKD stage. Because many of the patients who underwent AFCA
did not have advanced CKD, this study might not be able to
represent a broad spectrum of patients with an impaired renal
function. We could not investigate the mechanism of the
association between renal function improvement and mainte-
nance of sinus rhythm by comparing the change in hemody-
namics and inﬂammatorymarkers; however, it was not themain
subject of this study.
Conclusions
AF catheter ablation signiﬁcantly improved renal function
during the 5-year follow-up. Reduction in AF burden, even with
repeat ablation sessions, was independently associated with
an improvement in renal function in patients without preexist-
ing diabetes mellitus as well as in the overall patients.
However, patients with preexisting diabetes mellitus had no
beneﬁcial improvement in renal function; however, sinus
rhythm was maintained after repeat ablation sessions.
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Supplemental Material 
 
Table S1. Logistic regression analysis for variables predicting an improved renal 
function (eGFR5yr≥1) after 5-years of follow-up (n=2,284). 
 
Univariate Multivariate Model  
OR (95% CI) P-value OR (95% CI) P-value 
Age 0.979 (0.972-0.987) <0.001 0.980 (0.972-0.989) <0.001 
Male  0.899 (0.747-1.082) 0.261   
Body mass index 1.016 (0.988-1.044) 0.264   
CHA2DS2VASc score 0.952 (0.902-1.004) 0.070   
CHF 0.717 (0.484-1.063) 0.098   
Hypertension 0.846 (0.718-0.998) 0.047 1.008 (0.829-1.226) 0.938 
Diabetes 0.897 (0.721-1.116) 0.329   
Stroke/TIA 0.955 (0.737-1.236) 0.725   
Vascular disease 1.041 (0.825-1.312) 0.737   
ACEi/ARB use 0.814 (0.686-0.965) 0.018 0.885 (0.727-1.078) 0.224 
BB use 0.865 (0.722-1.037) 0.118   
Statin use 0.996 (0.830-1.195) 0.965   
AFCA 1.844 (1.522-2.233) <0.001 1.845 (1.521-2.237) <0.001 
OR = odd radio, CI = confidence interval, CHF = congestive heart failure, TIA = transient 
ischemic attack, ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin type II 
receptor blocker, BB = beta blocker, AFCA = atrial fibrillation catheter ablation.  
 
 
 
 
Table S2. Logistic regression analysis for variables predicting an improved renal 
function (eGFR5yr>5) after 5-years of follow-up (n=2,284). 
 
Univariate Multivariate Model  
OR (95% CI) P-value OR (95% CI) P-value 
Age 0.979 (0.971-0.987) <0.001 0.980 (0.927-0.989) <0.001 
Male  0.840 (0.697-1.012) 0.067   
Body mass index 1.011 (0.983-1.039) 0.464   
CHA2DS2VASc score 0.949 (0.898-1.002) 0.060   
CHF 0.750 (0.502-1.121) 0.161   
Hypertension 0.825 (0.698-0.974) 0.024 1.033 (0.846-1.261) 0.750 
Diabetes 0.758 (0.605-0.949) 0.016 0.838 (0.663-1.060) 0.140 
Stroke/TIA 1.040 (0.802-1.350) 0.767   
Vascular disease 0.976 (0.771-1.235) 0.839   
ACEi/ARB use 0.784 (0.659-0.932) 0.006 0.857 (0.702-1.046) 0.129 
BB use 0.853 (0.710-1.026) 0.091   
Statin use 0.959 (0.797-1.154) 0.657   
AFCA 1.223 (1.010-1.481) 0.039 1.225 (1.010-1.486) 0.039 
OR = odd radio, CI = confidence interval, CHF = congestive heart failure, TIA = transient 
ischemic attack, ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin type II 
receptor blocker, BB = beta blocker, AFCA = atrial fibrillation catheter ablation.  
 
 
 
 
Table S3. Linear regression analysis for variables predicting a change in eGFR 
(eGFR5yr) after 5-years of follow-up (n=2,284). 
 Univariate Multivariate Model  
B (95% CI) P-value B (95% CI) P-value 
Age -0.200 (-0.263 to -0.136) <0.001 -0.173 (-0.240 to -0.105) <0.001 
Male  -1.398 (-2.886 to 0.090) 0.066   
Body mass index 0.239 (0.016 to 0.461) 0.035 0.256 (0.028 to 0.485) 0.028 
CHA2DS2VASc 
score 
-0.713 (-1.141 to -0.285) 0.001   
CHF -0.402 (-3.490 to 2.687) 0.799   
Hypertension -1.658 (-2.978 to -0.337) 0.014 0.568 (-1.017 to 2.153) 0.482 
Diabetes -2.394 (-4.141 to -0.647) 0.007 -1.576 (-3.368 to 0.216) 0.085 
Stroke/TIA -1.387 (-3.458 to 0.683) 0.189   
Vascular disease -0.471 (-2.338 to 1.395) 0.621   
ACEi/ARB use -2.214 (-3.576 to -0.852) 0.001 -1.614 (-3.172 to -0.056) 0.042 
BB use -2.060 (-3.506 to -0.613) 0.005 -1.723 (-3.199 to -0.246) 0.022 
Statin use -0.945 (-2.408 to 0.519) 0.206   
AFCA 2.553 (1.030 to 4.077) 0.001 2.439 (0.929 to 3.949) 0.002 
CI = confidence interval, CHF = congestive heart failure, TIA = transient ischemic attack, 
ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin type II receptor 
blocker, BB = beta blocker, AFCA = atrial fibrillation catheter ablation 
 
 
Table S4. Logistic regression analysis of the baseline risk factors predicting advanced 
CKD among the overall patients with AFCA (n=571). 
 Univariate Multivariate 
OR (95% CI) p-value OR (95% CI) p-value 
Age  1.111 (1.074-1.149) <0.001 1.105 (1.066-1.145) <0.001 
Male 1.142 (0.637-2.048) 0.655   
PAF at procedure 0.579 (0.345-0.970) 0.038 0.784 (0.427-1.440) 0.433 
Body mass index 1.046 (0.958-1.142) 0.318   
Body surface area 1.222 (0.279-5.355) 0.790   
CHA2DS2VASc score 1.535 (1.308-1.800) <0.001   
Congestive heart failure 2.440 (1.004-5.927) 0.049 2.057 (0.756-5.593) 0.158 
Hypertension 3.235 (1.816-5.763) <0.001 1.858 (0.987-3.497) 0.055 
Diabetes  2.711 (1.541-4.769) 0.001 1.542 (0.817-2.910) 0.181 
Stroke/TIA 1.376 (0.665-2.844) 0.389   
Vascular disease 1.945 (1.065-3.552) 0.030 0.952 (0.489-1.852) 0.885 
LA dimension  1.070 (1.026-1.115) 0.002 1.054 (1.001-1.110) 0.046 
LVEF 0.983 (0.954-1.013) 0.268   
E/Em 1.036 (0.992-1.081) 0.110   
CKD = chronic kidney disease, AFCA = atrial fibrillation catheter ablation, PAF = 
paroxysmal atrial fibrillation, TIA = transient ischemic attack, LA = left atrium, LVEF = left 
ventricular ejection fraction, E/Em = the ratio of the early diastolic mitral inflow velocity (E) 
to the early diastolic mitral annular velocity (Em)
Figure S1. Kaplan-Meier analysis of an AF/AT recurrence after a single AF ablation (A) and the last AF ablation (B) according to 
baseline advanced CKD.  
 
AF = atrial fibrillation, AT = atrial tachycardia, CKD = chronic kidney disease.  
